Richmond, Virginia, Jan. 14, 2026 (GLOBE NEWSWIRE) -- RICHMOND, Va., January 14, 2026 – Phlow Corp., a leading American pharmaceutical contract development and manufacturing organization (CDMO), today ...

Halo Pharma becomes a standalone drug product CDMO after the sale of Noramco’s API assets, adding sterile services by H2 2026 ...

Operating under the FDA's 503B pathway, the Apex facility will prioritize the production of generic shortage-listed ...

Scheduled for August 2025 completion, the initial $2-billion phase included construction of a 1-million-sq-ft complex with two drug substance manufacturing buildings, each containing four 20,000-liter ...

USP is developing digital reference standards to integrate into modern digital environments, enhancing regulatory confidence ...

The engagement will explore the use of cellular fermentation to make key starting materials required for pharmaceutical manufacturing. LONE TREE, CO, UNITED STATES ...

The Södertälje facility is a well-established drug substance (API) CDMO with more than 45 employees and a strong track record in small molecule active pharmaceutical ingredients. The facility supports ...

C ambridge, UK-based AstraZeneca plans to invest $2 billion to expand its long-standing manufacturing footprint in Maryland. The project includes an expansion of its flagship biologics manufacturing ...

VILNIUS, LT / ACCESS Newswire / July 29, 2025 / Diorasis Therapeutics (“DTx”), a preclinical-stage biotechnology company developing gene therapies for ophthalmic diseases, has entered into a strategic ...

President Donald Trump signed an executive order to incentivize drug manufacturing in the U.S. The order comes ahead of Trump's planned tariffs on pharmaceuticals imported into the U.S. U.S.

In just three months, Phlow and Enveda generated and analyzed nearly 20,000 unique reactions, creating one of the largest high-quality datasets of its kind. The resulting uniform dataset is ...